[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"blog-post-enicepatide-ct-388-roche-zh":3},{"_path":4,"_dir":5,"_draft":6,"_partial":6,"_locale":7,"title":8,"description":9,"cat":10,"icon":11,"accent":12,"date":13,"dateLabel":14,"read":15,"author":16,"image":17,"body":18,"_type":948,"_id":949,"_source":950,"_file":951,"_stem":952,"_extension":953},"\u002Fblog\u002Fzh\u002Fenicepatide-ct-388-roche","zh",false,"","Enicepatide（罗氏的 CT-388）：它到底是什么，又和司美格鲁肽、替尔泊肽、Retatrutide 及胰淀素类药物怎么比","本文属于一般性科普，不是医疗建议，也不是鼓励你去获取或使用任何物质。Enicepatide 是一款在研药物，全球任何地方都尚未获批，无法合法购买，也开不出处方。文中没有任何剂量、叠加或购买指导；下面那些跨试验的数字来自各自独立的研究，并不是头对头比较。","研究","tabler:flask-2","#6D5FC7","2026-07-24","2026年7月","11 min","myPeptides Team","\u002Fassets\u002Fenicepatide_hero.png",{"type":19,"children":20,"toc":938},"root",[21,28,48,55,74,103,149,154,159,178,231,243,262,267,279,507,512,595,607,613,618,627,659,664,750,762,767,795,824,829,847,852],{"type":22,"tag":23,"props":24,"children":25},"element","p",{},[26],{"type":27,"value":9},"text",{"type":22,"tag":23,"props":29,"children":30},{},[31,33,39,41,46],{"type":27,"value":32},"如果你一直盯着减肥药的研发管线，2026 年美国糖尿病协会（ADA）在新奥尔良的年会上冒出了一个新名字，之后就赖在头条上不走了：",{"type":22,"tag":34,"props":35,"children":36},"strong",{},[37],{"type":27,"value":38},"enicepatide",{"type":27,"value":40},"。它是罗氏的，注射剂，每周一次；在二期试验里做出了 ",{"type":22,"tag":34,"props":42,"children":43},{},[44],{"type":27,"value":45},"48 周减重约 22.5%",{"type":27,"value":47}," 的成绩——这种数字，此前只有替尔泊肽和 Retatrutide 摸到过。这篇就是大白话版：enicepatide 是什么，它在司美格鲁肽、替尔泊肽、Retatrutide、Cagrilintide 和 Eloralintide 之间站在哪个位置，研究到底走到了哪一步，以及把它和别的东西凑一起到底有没有道理——也就是 CagriSema 那个问题，还有生物黑客论坛上“reta + cagri”那个问题。",{"type":22,"tag":49,"props":50,"children":52},"h2",{"id":51},"enicepatide-到底是什么",[53],{"type":27,"value":54},"Enicepatide 到底是什么",{"type":22,"tag":23,"props":56,"children":57},{},[58,60,65,67,72],{"type":27,"value":59},"Enicepatide 是一个你也许早就认识的分子的新名字——它的代号是 ",{"type":22,"tag":34,"props":61,"children":62},{},[63],{"type":27,"value":64},"CT-388",{"type":27,"value":66},"（也写作 RO7795068）。它随着罗氏 2023 年 12 月以约 27 亿美元收购 ",{"type":22,"tag":34,"props":68,"children":69},{},[70],{"type":27,"value":71},"Carmot Therapeutics",{"type":27,"value":73}," 一起进了门，此后罗氏／基因泰克一直在大力推进它。",{"type":22,"tag":23,"props":75,"children":76},{},[77,79,84,86,93,95,101],{"type":27,"value":78},"从机制上说，它是一款 ",{"type":22,"tag":34,"props":80,"children":81},{},[82],{"type":27,"value":83},"每周一次皮下注射的 GLP-1\u002FGIP 双受体激动剂",{"type":27,"value":85},"——一个分子同时打开两种与食欲和血糖有关的肠道激素受体。这一点它和 ",{"type":22,"tag":87,"props":88,"children":90},"a",{"href":89},"\u002Fglp1\u002Ftirzepatide",[91],{"type":27,"value":92},"替尔泊肽",{"type":27,"value":94}," 是一样的。真正让它与众不同的，是它",{"type":22,"tag":96,"props":97,"children":98},"em",{},[99],{"type":27,"value":100},"怎么",{"type":27,"value":102},"作用于这些受体：",{"type":22,"tag":104,"props":105,"children":106},"ul",{},[107,125],{"type":22,"tag":108,"props":109,"children":110},"li",{},[111,116,118,123],{"type":22,"tag":34,"props":112,"children":113},{},[114],{"type":27,"value":115},"均衡，而不是偏科。",{"type":27,"value":117}," 替尔泊肽对 GIP 受体的偏重远远大过 GLP-1。Enicepatide 则被设计成对两者的激活大致",{"type":22,"tag":96,"props":119,"children":120},{},[121],{"type":27,"value":122},"相当",{"type":27,"value":124},"——这是一种真正不同的药理特征，而不只是同一个东西加了个强化版。",{"type":22,"tag":108,"props":126,"children":127},{},[128,133,135,140,142,147],{"type":22,"tag":34,"props":129,"children":130},{},[131],{"type":27,"value":132},"信号偏向（signalling-biased）。",{"type":27,"value":134}," 这是最技术性的那个卖点。Enicepatide 的设计意图，是在细胞内触发有用的“cAMP”信号，同时几乎不去招募 ",{"type":22,"tag":34,"props":136,"children":137},{},[138],{"type":27,"value":139},"β-抑制蛋白（β-arrestin）",{"type":27,"value":141},"——正是这个蛋白，平时会把受体拽回细胞内部、再把它关掉。这种“内化”少了，受体就能更久地保持响应；罗氏正是拿这个机制来解释这款药效果持久，以及减重曲线 ",{"type":22,"tag":34,"props":143,"children":144},{},[145],{"type":27,"value":146},"到 48 周都还没触顶",{"type":27,"value":148}," 这件事。",{"type":22,"tag":23,"props":150,"children":151},{},[152],{"type":27,"value":153},"你不用真懂这些生物化学，也能记住结论：enicepatide 是一款精修过的双重激动剂，主打每一针都尽量把药效撑得更久，而不是一个全新的药物门类。",{"type":22,"tag":49,"props":155,"children":157},{"id":156},"二期数据",[158],{"type":27,"value":156},{"type":22,"tag":23,"props":160,"children":161},{},[162,164,169,171,176],{"type":27,"value":163},"让所有人都为之一动的数据，来自一项二期研究（CT388-103），受试者是 ",{"type":22,"tag":34,"props":165,"children":166},{},[167],{"type":27,"value":168},"469 名",{"type":27,"value":170}," 超重或肥胖的成年人，在 48 周里用 ",{"type":22,"tag":34,"props":172,"children":173},{},[174],{"type":27,"value":175},"4 mg 到 24 mg",{"type":27,"value":177}," 五个剂量对比安慰剂。结果给出了一条漂亮的剂量-反应曲线，在最高剂量下：",{"type":22,"tag":104,"props":179,"children":180},{},[181,198],{"type":22,"tag":108,"props":182,"children":183},{},[184,189,191,196],{"type":22,"tag":34,"props":185,"children":186},{},[187],{"type":27,"value":188},"48 周经安慰剂校正的减重约 22.5%",{"type":27,"value":190},"（疗效估计目标），而且",{"type":22,"tag":34,"props":192,"children":193},{},[194],{"type":27,"value":195},"还没到平台期",{"type":27,"value":197},"——试验窗口关闭时，曲线仍在往下走。",{"type":22,"tag":108,"props":199,"children":200},{},[201,203,208,210,215,217,222,224,229],{"type":27,"value":202},"在 48 周仍用 24 mg 剂量的人里，",{"type":22,"tag":34,"props":204,"children":205},{},[206],{"type":27,"value":207},"95.7%",{"type":27,"value":209}," 至少减掉了 5% 的体重，",{"type":22,"tag":34,"props":211,"children":212},{},[213],{"type":27,"value":214},"87%",{"type":27,"value":216}," 减掉了 ≥10%，",{"type":22,"tag":34,"props":218,"children":219},{},[220],{"type":27,"value":221},"47.8%",{"type":27,"value":223}," 减掉了 ≥20%，",{"type":22,"tag":34,"props":225,"children":226},{},[227],{"type":27,"value":228},"26.1%",{"type":27,"value":230}," 减掉了 ≥30%。",{"type":22,"tag":23,"props":232,"children":233},{},[234,236,241],{"type":27,"value":235},"它并非没有副作用。和这一类药里的每一款一样，麻烦主要出在胃肠道——恶心、呕吐、腹泻——",{"type":22,"tag":34,"props":237,"children":238},{},[239],{"type":27,"value":240},"因不良事件而停药的比例为 5.9%",{"type":27,"value":242},"，安慰剂组则是 1.3%。这是个实打实的数字，但落在强效肠促胰素类药物的正常区间之内。",{"type":22,"tag":23,"props":244,"children":245},{},[246,248,253,255,260],{"type":27,"value":247},"凭着这份成绩，罗氏在 2026 年初启动了三期项目 ",{"type":22,"tag":34,"props":249,"children":250},{},[251],{"type":27,"value":252},"ENITH",{"type":27,"value":254},"，比较现实的上市时间大约在 ",{"type":22,"tag":34,"props":256,"children":257},{},[258],{"type":27,"value":259},"2030 年",{"type":27,"value":261}," 前后。换句话说：疗效信号很强，时间线很长。",{"type":22,"tag":49,"props":263,"children":265},{"id":264},"它和你已经认识的那些药差在哪",[266],{"type":27,"value":264},{"type":22,"tag":23,"props":268,"children":269},{},[270,272,277],{"type":27,"value":271},"先把整个格局摆出来。这里最有用的一点认知是：这些分子并不是在干同一件事。有些作用于肠促胰素受体（GLP-1、GIP、胰高血糖素）；另一些则模拟 ",{"type":22,"tag":34,"props":273,"children":274},{},[275],{"type":27,"value":276},"胰淀素（amylin）",{"type":27,"value":278},"——一种完全不同的饱腹感激素。",{"type":22,"tag":280,"props":281,"children":282},"table",{},[283,312],{"type":22,"tag":284,"props":285,"children":286},"thead",{},[287],{"type":22,"tag":288,"props":289,"children":290},"tr",{},[291,297,302,307],{"type":22,"tag":292,"props":293,"children":294},"th",{},[295],{"type":27,"value":296},"药物",{"type":22,"tag":292,"props":298,"children":299},{},[300],{"type":27,"value":301},"它是什么",{"type":22,"tag":292,"props":303,"children":304},{},[305],{"type":27,"value":306},"各自试验中的峰值减重",{"type":22,"tag":292,"props":308,"children":309},{},[310],{"type":27,"value":311},"进展",{"type":22,"tag":313,"props":314,"children":315},"tbody",{},[316,350,383,412,443,476],{"type":22,"tag":288,"props":317,"children":318},{},[319,328,340,345],{"type":22,"tag":320,"props":321,"children":322},"td",{},[323],{"type":22,"tag":34,"props":324,"children":325},{},[326],{"type":27,"value":327},"Enicepatide（CT-388）",{"type":22,"tag":320,"props":329,"children":330},{},[331,333,338],{"type":27,"value":332},"均衡、信号偏向的 ",{"type":22,"tag":34,"props":334,"children":335},{},[336],{"type":27,"value":337},"GLP-1\u002FGIP",{"type":27,"value":339}," 双重激动剂（罗氏）",{"type":22,"tag":320,"props":341,"children":342},{},[343],{"type":27,"value":344},"48 周约 22.5%",{"type":22,"tag":320,"props":346,"children":347},{},[348],{"type":27,"value":349},"三期（ENITH）",{"type":22,"tag":288,"props":351,"children":352},{},[353,361,373,378],{"type":22,"tag":320,"props":354,"children":355},{},[356],{"type":22,"tag":34,"props":357,"children":358},{},[359],{"type":27,"value":360},"司美格鲁肽",{"type":22,"tag":320,"props":362,"children":363},{},[364,366,371],{"type":27,"value":365},"纯 ",{"type":22,"tag":34,"props":367,"children":368},{},[369],{"type":27,"value":370},"GLP-1",{"type":27,"value":372}," 激动剂（诺和诺德——Wegovy\u002FOzempic）",{"type":22,"tag":320,"props":374,"children":375},{},[376],{"type":27,"value":377},"68 周约 15%",{"type":22,"tag":320,"props":379,"children":380},{},[381],{"type":27,"value":382},"已获批",{"type":22,"tag":288,"props":384,"children":385},{},[386,393,403,408],{"type":22,"tag":320,"props":387,"children":388},{},[389],{"type":22,"tag":34,"props":390,"children":391},{},[392],{"type":27,"value":92},{"type":22,"tag":320,"props":394,"children":395},{},[396,401],{"type":22,"tag":34,"props":397,"children":398},{},[399],{"type":27,"value":400},"GIP\u002FGLP-1",{"type":27,"value":402}," 双重激动剂，偏重 GIP（礼来——Zepbound\u002FMounjaro）",{"type":22,"tag":320,"props":404,"children":405},{},[406],{"type":27,"value":407},"约 20–25%",{"type":22,"tag":320,"props":409,"children":410},{},[411],{"type":27,"value":382},{"type":22,"tag":288,"props":413,"children":414},{},[415,423,433,438],{"type":22,"tag":320,"props":416,"children":417},{},[418],{"type":22,"tag":34,"props":419,"children":420},{},[421],{"type":27,"value":422},"Retatrutide",{"type":22,"tag":320,"props":424,"children":425},{},[426,431],{"type":22,"tag":34,"props":427,"children":428},{},[429],{"type":27,"value":430},"GLP-1\u002FGIP\u002F胰高血糖素",{"type":27,"value":432}," 三重激动剂（礼来）",{"type":22,"tag":320,"props":434,"children":435},{},[436],{"type":27,"value":437},"最高约 24%+",{"type":22,"tag":320,"props":439,"children":440},{},[441],{"type":27,"value":442},"三期",{"type":22,"tag":288,"props":444,"children":445},{},[446,454,466,471],{"type":22,"tag":320,"props":447,"children":448},{},[449],{"type":22,"tag":34,"props":450,"children":451},{},[452],{"type":27,"value":453},"Cagrilintide",{"type":22,"tag":320,"props":455,"children":456},{},[457,459,464],{"type":27,"value":458},"长效 ",{"type":22,"tag":34,"props":460,"children":461},{},[462],{"type":27,"value":463},"胰淀素",{"type":27,"value":465}," 类似物（诺和诺德）",{"type":22,"tag":320,"props":467,"children":468},{},[469],{"type":27,"value":470},"单用效果一般；与司美格鲁肽搭配即 CagriSema",{"type":22,"tag":320,"props":472,"children":473},{},[474],{"type":27,"value":475},"三期（作为 CagriSema）",{"type":22,"tag":288,"props":477,"children":478},{},[479,487,498,503],{"type":22,"tag":320,"props":480,"children":481},{},[482],{"type":22,"tag":34,"props":483,"children":484},{},[485],{"type":27,"value":486},"Eloralintide",{"type":22,"tag":320,"props":488,"children":489},{},[490,492,496],{"type":27,"value":491},"选择性 ",{"type":22,"tag":34,"props":493,"children":494},{},[495],{"type":27,"value":463},{"type":27,"value":497}," 激动剂（礼来）",{"type":22,"tag":320,"props":499,"children":500},{},[501],{"type":27,"value":502},"48 周约 9.5–20.1%",{"type":22,"tag":320,"props":504,"children":505},{},[506],{"type":27,"value":442},{"type":22,"tag":23,"props":508,"children":509},{},[510],{"type":27,"value":511},"再老实补几句，因为一张表会把真实的差异抹平：",{"type":22,"tag":104,"props":513,"children":514},{},[515,532,554,579],{"type":22,"tag":108,"props":516,"children":517},{},[518,522,524,530],{"type":22,"tag":34,"props":519,"children":520},{},[521],{"type":27,"value":360},{"type":27,"value":523}," 是那个单受体的原型。之后所有更新的药，某种意义上都是在回答一个问题：“我们能不能打赢纯 GLP-1？”背景可以看我们的 ",{"type":22,"tag":87,"props":525,"children":527},{"href":526},"\u002Fglp1\u002Fsemaglutide",[528],{"type":27,"value":529},"司美格鲁肽资料页",{"type":27,"value":531},"。",{"type":22,"tag":108,"props":533,"children":534},{},[535,539,541,546,548,553],{"type":22,"tag":34,"props":536,"children":537},{},[538],{"type":27,"value":92},{"type":27,"value":540}," 第一个证明了两个受体强过一个。Enicepatide 的说法是，它对同样这两个受体的作用",{"type":22,"tag":96,"props":542,"children":543},{},[544],{"type":27,"value":545},"更均衡、也更持久",{"type":27,"value":547},"——它要对标的那位在位者，见 ",{"type":22,"tag":87,"props":549,"children":550},{"href":89},[551],{"type":27,"value":552},"替尔泊肽资料页",{"type":27,"value":531},{"type":22,"tag":108,"props":555,"children":556},{},[557,561,563,569,571,577],{"type":22,"tag":34,"props":558,"children":559},{},[560],{"type":27,"value":422},{"type":27,"value":562}," 加上了第三个受体——胰高血糖素，目前在所有肠促胰素类药里减重数字最高。它最新的三期读数，我们在 ",{"type":22,"tag":87,"props":564,"children":566},{"href":565},"\u002Fblog\u002Fretatrutide-triumph-2-3-results",[567],{"type":27,"value":568},"Retatrutide TRIUMPH-2 与 TRIUMPH-3",{"type":27,"value":570}," 里讲过，完整图景则在 ",{"type":22,"tag":87,"props":572,"children":574},{"href":573},"\u002Fglp1\u002Fretatrutide",[575],{"type":27,"value":576},"Retatrutide 资料页",{"type":27,"value":578},"。Enicepatide 并不想在力气上压过它，而是想用一套更干净的双受体设计，做出相近的效果。",{"type":22,"tag":108,"props":580,"children":581},{},[582,587,589,593],{"type":22,"tag":34,"props":583,"children":584},{},[585],{"type":27,"value":586},"Cagrilintide 和 Eloralintide",{"type":27,"value":588}," 根本不是肠促胰素——它们是 ",{"type":22,"tag":34,"props":590,"children":591},{},[592],{"type":27,"value":463},{"type":27,"value":594}," 药物，走的是另一条独立的饱腹通路。正是这个区别，才有了下一节的存在。",{"type":22,"tag":23,"props":596,"children":597},{},[598,600,605],{"type":27,"value":599},"有一句提醒，请你从头到尾记着：",{"type":22,"tag":34,"props":601,"children":602},{},[603],{"type":27,"value":604},"这些数字没有一个是头对头得来的。",{"type":27,"value":606}," 不同的试验、不同的时长、不同的人群。一项研究里的 22.5% 和另一项里的 24%，并不能断定哪款药“更强”——只有一场直接对照的试验才能，而这类试验大多还没做过。",{"type":22,"tag":49,"props":608,"children":610},{"id":609},"它能叠加吗cagrisemareta-cagri以及罗氏自己的答案",[611],{"type":27,"value":612},"它能叠加吗？CagriSema、“reta + cagri”，以及罗氏自己的答案",{"type":22,"tag":23,"props":614,"children":615},{},[616],{"type":27,"value":617},"这是把论坛塞满的那个问题，值得好好答一答，因为流行的说法里有点乱。",{"type":22,"tag":23,"props":619,"children":620},{},[621],{"type":22,"tag":622,"props":623,"children":626},"img",{"alt":624,"src":625},"一条肠促胰素式的缎带和一个小小的胰淀素环，一起汇入同一支注射笔——肠促胰素叠加胰淀素的组合思路","\u002Fassets\u002Fenicepatide_combo.png",[],{"type":22,"tag":23,"props":628,"children":629},{},[630,632,637,639,643,645,650,652,657],{"type":27,"value":631},"先把分类捋清楚。",{"type":22,"tag":34,"props":633,"children":634},{},[635],{"type":27,"value":636},"CagriSema 并不是两款 GLP-1 药物",{"type":27,"value":638},"——它是一款 GLP-1 药物（司美格鲁肽）加一款 ",{"type":22,"tag":34,"props":640,"children":641},{},[642],{"type":27,"value":463},{"type":27,"value":644}," 药物（cagrilintide），装在同一支笔里，作用于两套",{"type":22,"tag":96,"props":646,"children":647},{},[648],{"type":27,"value":649},"不同",{"type":27,"value":651},"的激素系统。这才是关键的套路：整个行业都在朝 ",{"type":22,"tag":34,"props":653,"children":654},{},[655],{"type":27,"value":656},"“肠促胰素 + 胰淀素”",{"type":27,"value":658}," 这个下一步汇拢，因为这两条通路是以互补的方式抑制食欲，而不是往同一个受体上死磕。",{"type":22,"tag":23,"props":660,"children":661},{},[662],{"type":27,"value":663},"看懂了这一点，叠加这个问题就不言自明了：",{"type":22,"tag":104,"props":665,"children":666},{},[667,689,727],{"type":22,"tag":108,"props":668,"children":669},{},[670,675,677,681,683,687],{"type":22,"tag":34,"props":671,"children":672},{},[673],{"type":27,"value":674},"把两款肠促胰素药叠在一起，基本没意义。",{"type":27,"value":676}," Enicepatide 已经把 GLP-1 和 GIP 都覆盖了。再加 ",{"type":22,"tag":87,"props":678,"children":679},{"href":526},[680],{"type":27,"value":360},{"type":27,"value":682},"（更多 GLP-1）或 ",{"type":22,"tag":87,"props":684,"children":685},{"href":89},[686],{"type":27,"value":92},{"type":27,"value":688},"（同样这两个受体加码），并不会打开一条新机制——只是把你本来就在打的受体又加了一倍，往往是副作用涨了、好处却没多多少。这也是为什么没有哪个正经项目会去研发“GLP-1 再加一个 GLP-1”。",{"type":22,"tag":108,"props":690,"children":691},{},[692,697,699,704,706,711,713,718,720,725],{"type":22,"tag":34,"props":693,"children":694},{},[695],{"type":27,"value":696},"理性的搭档是胰淀素。",{"type":27,"value":698}," 而真正露馅的地方就在这儿：罗氏正是这么干的。在 enicepatide 之外，它还在研发 ",{"type":22,"tag":34,"props":700,"children":701},{},[702],{"type":27,"value":703},"petrelintide",{"type":27,"value":705},"，一款胰淀素类似物（单用时 42 周减重约 9%）；并在 ",{"type":22,"tag":34,"props":707,"children":708},{},[709],{"type":27,"value":710},"2026 年年中启动了一项把两者合用的二期试验",{"type":27,"value":712},"——固定剂量的 enicepatide + petrelintide，摆明了就是要在更好耐受的前提下追更多减重。诺和诺德那一版思路叫 ",{"type":22,"tag":34,"props":714,"children":715},{},[716],{"type":27,"value":717},"CagriSema",{"type":27,"value":719},"；礼来那一版是 ",{"type":22,"tag":34,"props":721,"children":722},{},[723],{"type":27,"value":724},"替尔泊肽 + eloralintide",{"type":27,"value":726},"；罗氏这一版是 enicepatide + petrelintide。同一个菜谱，三家厨房。",{"type":22,"tag":108,"props":728,"children":729},{},[730,735,737,741,743,748],{"type":22,"tag":34,"props":731,"children":732},{},[733],{"type":27,"value":734},"生物黑客那套“reta + cagri”叠加",{"type":27,"value":736},"——",{"type":22,"tag":87,"props":738,"children":739},{"href":573},[740],{"type":27,"value":422},{"type":27,"value":742}," 加 cagrilintide——是同一套逻辑在灰色市场的回声：一款三重肠促胰素加一款胰淀素。从机制上说，它和那几家公司在试的东西押着同一个韵。但实际上，它完全是另一回事：",{"type":22,"tag":34,"props":744,"children":745},{},[746],{"type":27,"value":747},"这种自己动手的版本没有任何受控的人体安全数据",{"type":27,"value":749},"，副作用（恶心、呕吐、脱水，以及随之而来的停药）也会一起叠加，而这种场景下的每一支西林瓶，都是身份和纯度都没保证的不受监管原料。一种组合在申办方的试验里药理上讲得通，并不能让自己配的那一版变得安全、剂量正确，或者合法。",{"type":22,"tag":23,"props":751,"children":752},{},[753,755,760],{"type":27,"value":754},"所以：enicepatide 能叠加吗？纸面上，合理的组合是 enicepatide ",{"type":22,"tag":34,"props":756,"children":757},{},[758],{"type":27,"value":759},"配一款胰淀素",{"type":27,"value":761},"，而不是再配一款 GLP-1——而这个组合，罗氏自己正在临床监督下搭建，比任何人能买到其中任何一块，都要早上好几年。",{"type":22,"tag":49,"props":763,"children":765},{"id":764},"这对今天的你意味着什么",[766],{"type":27,"value":764},{"type":22,"tag":23,"props":768,"children":769},{},[770,772,777,779,785,787,793],{"type":27,"value":771},"对时间线要看得清醒。Enicepatide 还处在 ",{"type":22,"tag":34,"props":773,"children":774},{},[775],{"type":27,"value":776},"在研阶段",{"type":27,"value":778},"。它在任何地方都没有获批，你开不到它的处方，三期项目指向的可能上市时间在 2030 年前后。眼下网上任何打着“enicepatide”或“CT-388”名号卖的东西，按定义就是身份和纯度不明的、未获批的灰色市场货——一份委员会的幻灯片、一项临床试验，替不了某个陌生人寄给你的那支西林瓶背书。想了解更大的法律图景，我们那篇讲",{"type":22,"tag":87,"props":780,"children":782},{"href":781},"\u002Fare-peptides-legal",[783],{"type":27,"value":784},"肽是否合法",{"type":27,"value":786},"的总览文把各个类别都梳了一遍，而",{"type":22,"tag":87,"props":788,"children":790},{"href":789},"\u002Fwhat-are-peptides",[791],{"type":27,"value":792},"什么是肽",{"type":27,"value":794},"则是从零讲起的入门。",{"type":22,"tag":23,"props":796,"children":797},{},[798,800,806,808,814,816,822],{"type":27,"value":799},"至于人们今天真正在追踪的那些药，中立的那部分就是算术。如果你想记录自己手上有什么、什么浓度、什么时候用的，",{"type":22,"tag":87,"props":801,"children":803},{"href":802},"\u002Fpeptides-list",[804],{"type":27,"value":805},"我们的肽追踪器",{"type":27,"value":807},"正是为这个而做；如果让你犯难的是复溶这一步，",{"type":22,"tag":87,"props":809,"children":811},{"href":810},"\u002Fcalculator",[812],{"type":27,"value":813},"我们的计算器",{"type":27,"value":815},"会在你知道西林瓶规格、又加了多少抑菌注射用水之后，把目标剂量换算成注射器上的单位数；又因为这些是每周一次的注射、药物水平会在两针之间起起落落，",{"type":22,"tag":87,"props":817,"children":819},{"href":818},"\u002Fplotter",[820],{"type":27,"value":821},"血药浓度曲线图",{"type":27,"value":823},"会把这条曲线画出来。这些都不是在推荐你去用任何东西——只是算术，老老实实的算术。",{"type":22,"tag":49,"props":825,"children":827},{"id":826},"一句话总结",[828],{"type":27,"value":826},{"type":22,"tag":23,"props":830,"children":831},{},[832,834,838,840,845],{"type":27,"value":833},"Enicepatide（CT-388）是罗氏那款均衡、信号偏向的 GLP-1\u002FGIP 激动剂，它二期约 22.5% 的减重，让它在替尔泊肽和 Retatrutide 旁边挣到了一个实打实的座位——设计上是更干净的双受体，通往市场的路却更长。更有意思的其实是组合这条线：整个领域已经走到了 ",{"type":22,"tag":34,"props":835,"children":836},{},[837],{"type":27,"value":656},{"type":27,"value":839},"，而罗氏自己的答案是 enicepatide ",{"type":22,"tag":34,"props":841,"children":842},{},[843],{"type":27,"value":844},"加 petrelintide",{"type":27,"value":846},"，不是 enicepatide 再加一款 GLP-1。把两款肠促胰素叠在一起是多余的；自己动手那版“reta + cagri”借走了对的思路，却一点安全数据都没借来。就目前而言，enicepatide 是一款值得盯着看的药，而不是一款能弄到手的药——因为你弄不到，而论坛卖给你的那一版，也不是做出这些数字的那一版。",{"type":22,"tag":49,"props":848,"children":850},{"id":849},"参考来源",[851],{"type":27,"value":849},{"type":22,"tag":104,"props":853,"children":854},{},[855,868,879,890,902,914,926],{"type":22,"tag":108,"props":856,"children":857},{},[858,860],{"type":27,"value":859},"罗氏，",{"type":22,"tag":87,"props":861,"children":865},{"href":862,"rel":863},"https:\u002F\u002Fwww.roche.com\u002Fmedia\u002Freleases\u002Fmed-cor-2026-01-27",[864],"nofollow",[866],{"type":27,"value":867},"Positive Phase II results for its dual GLP-1\u002FGIP receptor agonist CT-388 (enicepatide)",{"type":22,"tag":108,"props":869,"children":870},{},[871,872],{"type":27,"value":859},{"type":22,"tag":87,"props":873,"children":876},{"href":874,"rel":875},"https:\u002F\u002Fwww.roche.com\u002Fmedia\u002Freleases\u002Fmed-cor-2026-06-01",[864],[877],{"type":27,"value":878},"New data advancing its obesity portfolio at the ADA 2026 Scientific Sessions",{"type":22,"tag":108,"props":880,"children":881},{},[882,883],{"type":27,"value":859},{"type":22,"tag":87,"props":884,"children":887},{"href":885,"rel":886},"https:\u002F\u002Fwww.roche.com\u002Fmedia\u002Freleases\u002Fmed-cor-2026-03-05",[864],[888],{"type":27,"value":889},"Positive Phase II results for petrelintide, an amylin analog",{"type":22,"tag":108,"props":891,"children":892},{},[893,895],{"type":27,"value":894},"Medical Dialogues，",{"type":22,"tag":87,"props":896,"children":899},{"href":897,"rel":898},"https:\u002F\u002Fmedicaldialogues.in\u002Fnews\u002Findustry\u002Fpharma\u002Froche-obesity-drug-enicepatide-delivers-227-weight-loss-in-mid-stage-trial-challenges-wegovy-zepbound-172251",[864],[900],{"type":27,"value":901},"Roche obesity drug enicepatide delivers 22.7% weight loss in mid-stage trial",{"type":22,"tag":108,"props":903,"children":904},{},[905,907],{"type":27,"value":906},"PMC／同行评审文献，",{"type":22,"tag":87,"props":908,"children":911},{"href":909,"rel":910},"https:\u002F\u002Fpmc.ncbi.nlm.nih.gov\u002Farticles\u002FPMC12771327\u002F",[864],[912],{"type":27,"value":913},"Effects of CT-388, a once-weekly signaling-biased dual GLP-1\u002FGIP receptor agonist",{"type":22,"tag":108,"props":915,"children":916},{},[917,919],{"type":27,"value":918},"礼来，",{"type":22,"tag":87,"props":920,"children":923},{"href":921,"rel":922},"https:\u002F\u002Flilly.gcs-web.com\u002Fnews-releases\u002Fnews-release-details\u002Flillys-selective-amylin-agonist-eloralintide-demonstrated",[864],[924],{"type":27,"value":925},"Selective amylin agonist eloralintide — Phase 2 results",{"type":22,"tag":108,"props":927,"children":928},{},[929,931],{"type":27,"value":930},"HCPLive，",{"type":22,"tag":87,"props":932,"children":935},{"href":933,"rel":934},"https:\u002F\u002Fwww.hcplive.com\u002Fview\u002Fcagrisema-achieves-22-7-weight-loss-in-phase-3-redefine-1-trial",[864],[936],{"type":27,"value":937},"CagriSema achieves 22.7% weight loss in Phase 3 REDEFINE 1",{"title":7,"searchDepth":939,"depth":939,"links":940},2,[941,942,943,944,945,946,947],{"id":51,"depth":939,"text":54},{"id":156,"depth":939,"text":156},{"id":264,"depth":939,"text":264},{"id":609,"depth":939,"text":612},{"id":764,"depth":939,"text":764},{"id":826,"depth":939,"text":826},{"id":849,"depth":939,"text":849},"markdown","content:blog:zh:enicepatide-ct-388-roche.md","content","blog\u002Fzh\u002Fenicepatide-ct-388-roche.md","blog\u002Fzh\u002Fenicepatide-ct-388-roche","md"]